Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 503 word(s) 503 2020-12-15 07:25:22

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Xu, C. Glanzmann Thrombasthenia. Encyclopedia. Available online: (accessed on 23 June 2024).
Xu C. Glanzmann Thrombasthenia. Encyclopedia. Available at: Accessed June 23, 2024.
Xu, Camila. "Glanzmann Thrombasthenia" Encyclopedia, (accessed June 23, 2024).
Xu, C. (2020, December 23). Glanzmann Thrombasthenia. In Encyclopedia.
Xu, Camila. "Glanzmann Thrombasthenia." Encyclopedia. Web. 23 December, 2020.
Glanzmann Thrombasthenia

Glanzmann thrombasthenia is a bleeding disorder that is characterized by prolonged or spontaneous bleeding starting from birth.

genetic conditions

1. Introduction

People with Glanzmann thrombasthenia tend to bruise easily, have frequent nosebleeds (epistaxis), and may bleed from the gums. They may also develop red or purple spots on the skin caused by bleeding underneath the skin (petechiae) or swelling caused by bleeding within tissues (hematoma). Glanzmann thrombasthenia can also cause prolonged bleeding following injury, trauma, or surgery (including dental work). Women with this condition can have prolonged and sometimes abnormally heavy menstrual bleeding. Affected women also have an increased risk of excessive blood loss during pregnancy and childbirth.

About a quarter of individuals with Glanzmann thrombasthenia have bleeding in the gastrointestinal tract, which often occurs later in life. Rarely, affected individuals have bleeding inside the skull (intracranial hemorrhage) or joints (hemarthrosis).

The severity and frequency of the bleeding episodes in Glanzmann thrombasthenia can vary greatly among affected individuals, even in the same family. Spontaneous bleeding tends to become less frequent with age.

2. Frequency

Glanzmann thrombasthenia is estimated to affect 1 in one million individuals worldwide, but may be more common in certain groups, including those of Romani ethnicity, particularly people within the French Manouche community.

3. Causes

Mutations in the ITGA2B or ITGB3 gene cause Glanzmann thrombasthenia. These genes provide instructions for making the two parts (subunits) of a receptor protein called integrin alphaIIb/beta3 (αIIbβ3). This protein is abundant on the surface of platelets. Platelets are small cells that circulate in blood and are an essential component of blood clots. During clot formation, integrin αIIbβ3 helps platelets bind together. Blood clots protect the body after injury by sealing off damaged blood vessels and preventing further blood loss.

ITGA2B or ITGB3 gene mutations result in a shortage (deficiency) of functional integrin αIIbβ3. As a result, platelets cannot clump together to form a blood clot, leading to prolonged bleeding.

Three types of Glanzmann thrombasthenia have been classified according to the amount of integrin αIIbβ3 that is available. People with type I (the most common type) have less than 5 percent of normal integrin αIIbβ3 levels, people with type II have between 5 and 20 percent of normal integrin αIIbβ3 levels, and people with the variant type have adequate integrin αIIbβ3 levels but produce only nonfunctional integrin.

Some people with Glanzmann thrombasthenia do not have an identified mutation in either the ITGA2B or ITGB3 gene; the cause of the disorder in these individuals is unknown.

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

  • deficiency of glycoprotein complex IIb-IIIa

  • deficiency of platelet fibrinogen receptor

  • Glanzmann disease

  • Glanzmann-Naegeli disorder

  • glycoprotein IIb/IIIa defect

  • hereditary hemorrhagic thrombasthenia

  • hereditary thrombasthenia

  • platelet fibrinogen receptor deficiency


  1. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review ofITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, andmouse models. Blood. 2011 Dec 1;118(23):5996-6005. doi:10.1182/blood-2011-07-365635.
  2. Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, Goudemand J,Gruel Y, Benabdallah-Guerida S, Latger-Cannard V, Négrier C, Nugent D, Oiron RD, Rand ML, Sié P, Trossaert M, Alberio L, Martins N, Sirvain-Trukniewicz P, CoulouxA, Canault M, Fronthroth JP, Fretigny M, Nurden P, Heilig R, Vinciguerra C.Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in GlanzmannThrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort. Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.
  3. Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the artand future directions. Semin Thromb Hemost. 2013 Sep;39(6):642-55. doi:10.1055/s-0033-1353393.
  4. Pillitteri D, Pilgrimm AK, Kirchmaier CM. Novel Mutations in the GPIIb andGPIIIa Genes in Glanzmann Thrombasthenia. Transfus Med Hemother.2010;37(5):268-277.
  5. Sandrock-Lang K, Oldenburg J, Wiegering V, Halimeh S, Santoso S, Kurnik K,Fischer L, Tsakiris DA, Sigl-Kraetzig M, Brand B, Bührlen M, Kraetzer K, Deeg N, Hund M, Busse E, Kahle A, Zieger B. Characterisation of patients with Glanzmannthrombasthenia and identification of 17 novel mutations. Thromb Haemost. 2015Apr;113(4):782-91. doi: 10.1160/TH14-05-0479.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 313
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 23 Dec 2020
Video Production Service